STOCK TITAN

Amicus Therapeutics (FOLD) 10-K Filings

FOLD

Here are the 10-K annual reports from Amicus Therapeutics, Inc (FOLD) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

A 10-K covers the audited annual report, with the full financial statements, so if you follow FOLD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full FOLD filings page.

Rhea-AI Summary

Amicus Therapeutics files its annual report highlighting a pending all-cash acquisition by BioMarin and continued growth in rare-disease therapies. Under a December 2025 merger agreement, BioMarin will acquire Amicus for $14.50 per share in cash, after which Amicus will become a wholly owned subsidiary and its stock will cease trading publicly, contingent on shareholder and regulatory approvals.

Commercial performance is led by Fabry drug Galafold, which generated $521.7 million in 2025 revenue, up $63.6 million year over year, and Pompe therapy Pombiliti + Opfolda, with $112.5 million in 2025 revenue, an increase of $42.3 million. Cash, cash equivalents and marketable securities totaled $293.5 million as of December 31 2025, supporting ongoing commercialization and pipeline work, including the U.S. license for Phase 3 kidney candidate DMX‑200. The company also emphasizes extensive patent protection, global regulatory approvals, and a long list of risk factors spanning merger completion, competition, pricing, regulation, financing needs, and reliance on third parties.